the cross-sectional and longitudinal associations of diabetic retinopathy with cognitive function...
Post on 05-Jan-2016
215 Views
Preview:
TRANSCRIPT
The Cross-sectional and Longitudinal Associations of Diabetic Retinopathy With
Cognitive Function and Brain MRI Findings: The Action to Control Cardiovascular Risk in
Diabetes (ACCORD) Trial
Featured Article:
Christina E. Hugenschmidt, James F. Lovato, Walter T. Ambrosius, R. Nick Bryan, Hertzel C. Gerstein, Karen R. Horowitz, Lenore J. Launer,
Ronald M. Lazar, Anne M. Murray, Emily Y. Chew, Ronald P. Danis, Jeff D. Williamson, Michael E. Miller, and Jingzhong Ding
Diabetes Care Volume 37: 3244-3252
December, 2014
STUDY OBJECTIVE
• Data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was used to determine whether diabetic retinopathy at baseline predicted changes in brain structure or cognition 40 months later
Hugenschmidt C. E. et al. Diabetes Care 2014;37:3244-3252
STUDY DESIGN AND METHODS
• Participants from the ACCORD-MIND and ACCORD-Eye substudies were included in analyses of cognition and MRI-derived brain variables
• Retinopathy was categorized as none, mild nonproliferative, or moderate/severe
• Tests of cognition included:• Mini-Mental State Examination (MMSE)• Digit Symbol Substitution Test (DSST)• Rey Auditory Verbal Learning Test• Stroop test
• Primary brain outcomes were gray matter and abnormal white matter volumes
Hugenschmidt C. E. et al. Diabetes Care 2014;37:3244-3252
Hugenschmidt C. E. et al. Diabetes Care 2014;37:3244-3252
RESULTS
• Baseline retinopathy was associated with lower gray matter volume
• Baseline retinopathy predicted a greater change in MMSE and DSST scores at 40 months in each retinopathy category
Hugenschmidt C. E. et al. Diabetes Care 2014;37:3244-3252
CONCLUSIONS
• Diabetic retinopathy is associated with future cognitive decline in people with type 2 diabetes
• Patients with type 2 diabetes and retinopathy represent a subgroup at higher risk for future cognitive decline
Hugenschmidt C. E. et al. Diabetes Care 2014;37:3244-3252
Hugenschmidt C. E. et al. Diabetes Care 2014;37:3244-3252
Hugenschmidt C. E. et al. Diabetes Care 2014;37:3244-3252
Hugenschmidt C. E. et al. Diabetes Care 2014;37:3244-3252
Hugenschmidt C. E. et al. Diabetes Care 2014;37:3244-3252
Hugenschmidt C. E. et al. Diabetes Care 2014;37:3244-3252
top related